Literature DB >> 6467141

Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.

V J Harvey, M L Slevin, B A Ponder, A J Blackshaw, P F Wrigley.   

Abstract

Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single-agent 5-fluorouracil. One partial response of 24 months was seen. Eleven patients were treated with single-agent Adriamycin (doxorubicin) after progression on 5-fluorouracil, and one partial response of 34 months was seen. It is concluded that 5-fluorouracil has only minimal activity in diffuse malignant mesothelioma. Preliminary data suggest that Adriamycin has little activity as a second-line agent.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6467141     DOI： 10.1002/1097-0142(19840915)54:6<961::aid-cncr2820540602>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  8 in total

1.  [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma].

Authors:  A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Pe'choux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-10

Review 2.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.

Authors:  D J Sugarbaker; J P Garcia; W G Richards; D H Harpole; E Healy-Baldini; M M DeCamp; S J Mentzer; M J Liptay; G M Strauss; S J Swanson
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

4.  A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma.

Authors:  B M Cantwell; C R Franks; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.

Authors:  G Falkson; M Hunt; E C Borden; J A Hayes; C I Falkson; T J Smith
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

6.  Investigational approaches for mesothelioma.

Authors:  Veerle F Surmont; Eric R E van Thiel; Karim Vermaelen; Jan P van Meerbeeck
Journal:  Front Oncol       Date:  2011-08-22       Impact factor: 6.244

Review 7.  Chemotherapy for malignant pleural mesothelioma: past results and recent developments.

Authors:  S Tomek; S Emri; K Krejcy; C Manegold
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

8.  Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study.

Authors:  Takaya Ikeda; Shinnosuke Takemoto; Hiroaki Senju; Hiroshi Gyotoku; Hirokazu Taniguchi; Midori Shimada; Yosuke Dotsu; Yasuhiro Umeyama; Hiromi Tomono; Takeshi Kitazaki; Masaaki Fukuda; Hiroshi Soda; Hiroyuki Yamaguchi; Minoru Fukuda; Hiroshi Mukae
Journal:  Thorac Cancer       Date:  2020-05-28       Impact factor: 3.500
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.